Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carrie Cole

Physician Assistant Birmingham, AL Physician Assistant

NPI 1821369067 CMS profile 10910340

3536 Vann Rd Ste B, Birmingham, AL 35235

Open in the dashboard

General payments

$2,677

142 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carrie Cole of Birmingham, AL is reported in the CMS Open Payments database as having received $2,677 across 142 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $601 34
2024 General $974 50
2023 General $811 42
2022 General $276 15
2021 General $14 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carrie Cole
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Carrie Cole were reported at $601. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Carrie Cole Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $14 $132 $37–$438 $132
2022 $276 $155 $48–$522 $149
2023 $811 $167 $52–$557 $160
2024 $974 $178 $55–$600 $164
2025 $601 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $644 35 payments
  2. Lilly USA, LLC $434 24 payments
  3. Abbott Laboratories $297 13 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $207 10 payments
  5. Exact Sciences Corporation $190 11 payments
  6. Pfizer Inc. $175 10 payments
  7. Phathom Pharmaceuticals, Inc. $143 6 payments
  8. AstraZeneca Pharmaceuticals LP $123 7 payments
  9. GlaxoSmithKline, LLC. $85 5 payments
  10. Idorsia Pharmaceuticals US Inc $79 5 payments
  11. Other $299 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,656 141 payments
  2. Education $20 1 payment
Products named General payments · program years 2021–2025
  1. RYBELSUS $436 23 payments
  2. Ozempic $414 22 payments
  3. MOUNJARO $299 14 payments
  4. Kerendia $207 10 payments
  5. Cologuard Collection Kit $190 11 payments
  6. FreeStyle Libre 2 $159 7 payments
  7. JARDIANCE $135 10 payments
  8. FARXIGA $105 6 payments
  9. VOQUEZNA $105 5 payments
  10. NURTEC ODT $105 6 payments
  11. Other $1,090 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 104 drugs

Part D claims

4,536

Median for Physician Assistant: 241

Drug cost

$405,940

Median for Physician Assistant: $4,110

Branded share of claims

19.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 64 $68,459
Mounjaro Tirzepatide Brand 47 $56,364
Januvia Sitagliptin Phosphate Brand 64 $41,284
Ozempic Semaglutide Brand 32 $40,011
Jardiance Empagliflozin Brand 41 $34,960
Trulicity Dulaglutide Brand 18 $25,585
Tresiba Flextouch U-200 Insulin Degludec Brand 19 $23,067
Rybelsus Semaglutide Brand 13 $22,384
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $13,522
Tresiba Flextouch U-100 Insulin Degludec Brand 18 $10,281

The 10 drugs with the highest cost, of 104 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$36,040

Of which drugs: $2,404

Medicare patients

220

Average age 77

Services billed

813

149 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 45%
Ischemic heart disease 40%
Depression 34%
Chronic kidney disease 31%
Heart failure 25%
Atrial fibrillation 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 12 16 $1

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$109 47 —
Kerendia
$99 — —
VOQUEZNA
$94 — —
RYBELSUS
$83 13 —
JARDIANCE
$68 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

142 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record